Cerenome (PSTV) Non-Current Assets (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Non-Current Assets of $1.9 million for Q1 2026, up 58.92% year-over-year from $1.2 million in Q1 2025, and up 63.46% quarter-over-quarter from $1.2 million in Q4 2025.
Cerenome (PSTV) Non-Current Assets (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Non-Current Assets for 17 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 58.92% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $5.3 million (down 12.4% YoY), while the FY2025 annual figure was $1.2 million, down 15.94% from the prior year.
- Non-Current Assets climbed to $1.9 million in Q1 2026 per PSTV's latest filing, from $1.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $2.4 million in Q1 2022 and bottomed at $1.1 million in Q3 2025.
- Historically, Non-Current Assets has averaged $1.7 million across 5 years, with a median of $1.7 million in 2023.
- Annual changes were most pronounced in 2025 — Non-Current Assets plunged 37.99% — and 2026, when it soared 58.92%.
- Plus Therapeutics' Non-Current Assets stood at $2.0 million in 2022, then declined by 24.2% to $1.6 million in 2023, then decreased by 11.58% to $1.4 million in 2024, then decreased by 15.94% to $1.2 million in 2025, then surged by 63.46% to $1.9 million in 2026.
- Business Quant data shows PSTV's Non-Current Assets at $1.9 million in Q1 2026, $1.2 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 2.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.89 Mn |
| Dec 31, 2025 | 1.16 Mn |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.19 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.83 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Dec 31, 2023 | 1.55 Mn |
| Sep 30, 2023 | 1.69 Mn |
| Jun 30, 2023 | 1.83 Mn |
| Mar 31, 2023 | 2.01 Mn |
| Dec 31, 2022 | 2.05 Mn |
| Sep 30, 2022 | 2.23 Mn |
| Jun 30, 2022 | 2.38 Mn |
| Mar 31, 2022 | 2.41 Mn |
| Dec 31, 2021 | 2.26 Mn |
| Sep 30, 2021 | 2.65 Mn |
| Jun 30, 2021 | 2.83 Mn |